You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB04940
TypeSmall Molecule
DescriptionE7389 is being studied in the treatment of cancer. It belongs to the family of drugs called antitubulin agents. It is the synthetic form of Halichondrin B (NSC 609395), a macrocyclic polyether initially isolated from the sponge Halichondria okadai.
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
IndicationInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), head and neck cancer, lung cancer, prostate cancer, and sarcoma.
Structured Indications Not Available
PharmacodynamicsE7389, like its parent natural compound Halichondrin B, is classified as a tubulin depolymerizer, and it shows activity at least equal to the naturally occurring chemical. It acts to disrupt the polymerization of the microtubules necessary in mitosis.2 This general characteristic places E7389 in the group of drugs that includes Vinca alkaloids, dolastatins, cryptophycin, and so forth, but its tubulin interactions appear to be unique, and it was found to have greater activity against lung and breast tumors in animal studies than either the parent halichondrin B or paclitaxel.
Mechanism of actionE7389 can activate cellular apoptosis pathways under anchorage-independent and -dependent cell culture conditions. Prolonged mitotic blockage by E7389 can lead to apoptotic cell death of human cancer cells in vitro and can provide a mechanistic basis for the significant in vivo anticancer efficacy of E7389.
TargetKindPharmacological actionActionsOrganismUniProt ID
Apoptosis regulator Bcl-2ProteinunknownNot AvailableHumanP10415 details
Tubulin beta-1 chainProteinunknownNot AvailableHumanQ9H4B7 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004 Aug 15;64(16):5760-6. [PubMed:15313917 ]
  2. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005 Jul;4(7):1086-95. [PubMed:16020666 ]
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
1Active Not RecruitingTreatmentAdult Solid Neoplasm / Recurrent Ovarian Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage III Ovarian Cancer / Stage III Uterine Corpus Cancer / Stage IV Ovarian Cancer / Stage IV Uterine Corpus Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor-negative / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentPediatrics / Tumors, Solid1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentDistal Urethral Carcinoma / Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma / Metastatic Urothelial Carcinoma / Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Proximal Urethral Carcinoma / Recurrent Bladder Carcinoma / Recurrent Urethra Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage III Urethral Cancer / Stage IV Bladder Cancer / Stage IV Urethral Cancer / Ureter Carcinoma1
1, 2RecruitingTreatmentMetastatic Breast Cancer (MBC)2
1, 2Unknown StatusTreatmentNon Small Cell Lung Cancer (NSCLC)1
2Active Not RecruitingTreatmentCancer, Breast3
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentMetastatic Ureteral Neoplasm / Metastatic Urethral Neoplasm / Stage III Bladder Urothelial Carcinoma / Stage III Ureter Cancer / Stage III Urethral Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Ureter Cancer / Stage IV Urethral Cancer / Ureter Urothelial Carcinoma / Urethral Urothelial Carcinoma1
2Active Not RecruitingTreatmentRecurrent Salivary Gland Cancer / Stage IVA Salivary Gland Cancer / Stage IVB Salivary Gland Cancer / Stage IVC Salivary Gland Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Pancreatic Cancers / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Refractory Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentCancer, Breast2
2CompletedTreatmentCancer, Breast / Estrogen Receptor Positive Tumor1
2CompletedTreatmentCarcinoma of the Prostate1
2CompletedTreatmentFallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentHead and Neck Cancers1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Osteosarcoma1
2CompletedTreatmentSoft Tissue Sarcoma (STS)2
2Not Yet RecruitingTreatmentBRCA1 Mutations / BRCA2 Mutation / Cancer, Ovarian / Stage 4 Breast Cancer1
2RecruitingTreatmentRecurrent Breast Carcinoma / Stage IV Breast Cancer1
2RecruitingTreatmentRecurrent Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
3Active Not RecruitingTreatmentCancer of Breast / Cancer, Breast / HER2-Negative Breast Cancer / Triple Negative Breast Cancer (TNBC) / Tumors, Breast1
3CompletedTreatmentCancer, Breast1
Not AvailableRecruitingNot AvailableSoft Tissue Sarcoma (STS)1
Not AvailableRecruitingTreatmentBreast Carcinoma Metastatic to the Brain / Lung Carcinoma Metastatic to the Brain / Metastatic Malignant Neoplasm in the Adult Brain / Metastatic Malignant Neoplasm to the Adult Brain / Primary Brain Tumors / Stage IV Bladder Cancer / Stage IV Non-Small Cell Lung Cancer1
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Mass Spec (NIST)Not Available
Spectrum TypeDescriptionSplash Key
ClassificationNot classified


Pharmacological action
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
Uniprot ID:
Molecular Weight:
26265.66 Da
  1. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004 Aug 15;64(16):5760-6. [PubMed:15313917 ]
Pharmacological action
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
Uniprot ID:
Molecular Weight:
50326.56 Da
  1. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E: Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006 Dec;70(6):1866-75. Epub 2006 Aug 29. [PubMed:16940412 ]
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24